Study	Phase, study design, and sample size	Stage	EGFR mutation status	aCT, % receiving aCT	Treatment regimen	Primary end points	Median follow-up (years)	Outcome
BR 19	Phase 3, randomized, double-masked, placebo controlled (n=503)	IB-IIIA	Wild type and mutated, only 15 patients with mutation	Optional, 17%	Gefitinib vs placebo for 2 years	DFS, OS	4.7	No difference in DFS or OS; EGFR mutation not prognostic
RADIANT	Phase 3, randomized, double-masked, placebo controlled (n=973)	IB-IIIA	Positive by IHC or FISH, 161 with sensitizing mutation	Optional, 52.9%	Erlotinib vs placebo for 2 years	DFS	3.9	No difference in DFS, OS data immature. No difference in DFS in EGFRm subset
SELECT	Phase 2, single-arm, open-label (n=100)	IA-IIIA	All with sensitizing mutation	As per staging, not reported	Erlotinib for 2 years	2-year DFS	5.2	2-year DFS 88%
CTONG1104	Phase 3, randomized, open-label (n=222)	II-IIIA	All with sensitizing mutation	Offered to chemotherapy arm, 50%	Cisplatin+Vinorelbine for 4 cycles vs gefitinib for 2 years	DFS	6.4	DFS longer in gefitinib arm, no difference in OS
ADAURA	Phase 3, randomized, double-masked, placebo controlled (n=682)	IB-IIIA	All with sensitizing mutation	Optional, 60%	Osimertinib vs placebo for 3 years	DFS for stage II-III	1.84 for osimertinib, 1.24 for placebo	2-year DFS 90% in osimertinib arm vs 44% in placebo arm